Navigation Links
Brain Tumor Vaccine Shows Promise in Early Trial
Date:4/17/2012

By Maureen Salamon
HealthDay Reporter

TUESDAY, April 17 (HealthDay News) -- A vaccine made from brain cancer patients' own tumor cells led to a nearly 50 percent improvement in survival times for those stricken with glioblastoma multiforme, the same malignancy that claimed the life of U.S. Sen. Edward Kennedy, a new study suggests.

A phase 2 multicenter trial of about 40 patients with recurrent glioblastoma -- an aggressive brain cancer that typically kills patients within 15 months of diagnosis -- showed that the vaccine safely increased average survival to nearly 48 weeks, compared with about 33 weeks among patients who didn't receive the treatment. The six-month survival rate was 93 percent for the vaccinated group, compared with 68 percent for 86 other glioblastoma patients, who were treated with other therapies.

"We've done a lot of things for this kind of tumor in the last 40 or 50 years, all variations on different chemotherapies that haven't really panned out," said Dr. Jonas Sheehan, director of neuro-oncology at the Penn State Cancer Institute, who was not involved in the study. "What we've known needed to happen for a while now is a revolution -- a totally new way of approaching these tumors. This is an example of a totally new paradigm."

The study is scheduled to be presented Tuesday at the annual meeting of the American Association of Neurological Surgeons (AANS), in Miami.

About a quarter of the 18,500 brain tumors diagnosed each year are glioblastomas, which are more common in men and typically occur between the ages of 50 and 70, according to the AANS. Kennedy died of the malignancy in 2009, 15 months after his diagnosis. Surgery, radiation and chemotherapy are among the standard treatment options.

The vaccine used in the trial, known as HSPPC-96, was created with tumor cells from patients who had undergone surgery to remove as much tumor as possible. The vaccine was then injected into their bodies to induce an immune response against the tumor, said lead investigator Dr. Andrew Parsa, vice chairman of neurological surgery at University of California, San Francisco. Side effects among participants were minimal.

"It's the concept of chronic therapy, to turn this into a chronic disease like hypertension and diabetes," said Parsa, who noted that no drug companies funded the study. "It's the only therapy in the clinical realm that has a reasonable chance of doing this, because we can't give patients chemotherapy [because of toxicity] for unlimited amounts of time."

Parsa said the vaccine's impact, if validated with a randomized study in the near future, could be a "total game-changer."

Added Sheehan: "The hope is that we'll go from a survival of 15 months to a meaningful difference. We're looking to go from 15 months to five years, a quantum leap forward."

Because this study was to be presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

Visit the American Association of Neurological Surgeons for more on glioblastomas.

SOURCES: Andrew Parsa, M.D., Ph.D., professor and vice chairman, neurological surgery, University of California, San Francisco; Jonas Sheehan, M.D., director, neuro-oncology, Penn State Cancer Institute, Hershey, Pa.; April 17, 2012, presentation, abstract, American Association of Neurological Surgeons, annual meeting, Miami


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Football-related catastrophic brain injuries on the rise
2. Researchers Map Brain Regions Linked to Intelligence
3. Nonsurgical Method to Measure Brain Pressure Shows Promise
4. Dental X-Rays May Be Linked to Benign Brain Tumors
5. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
6. Why is traumatic brain injury increasing among the elderly?
7. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
8. Epilepsy Leads to More Brain Abnormalities Over Time
9. Study Suggests Vaccine May Help Kids With Brain Cancer
10. Our brains on food: From anorexia to obesity and everything in between
11. Northwestern study compares endovascular brain aneurysm repair devices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Brain Tumor Vaccine Shows Promise in Early Trial
(Date:6/28/2017)... ... June 28, 2017 , ... ... and financial planning assistance to clients in southern Montana, is announcing a focused ... Zoo Montana. , The outreach programs offered by Zoo Montana provide students with ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... financial consultations to communities in northern Virginia and DC, is announcing a cooperative ... for patients with Alzheimer’s and other disorders that lead to memory impairment. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the ... to the position of Executive Vice President, Sales and Marketing. Finnegan is a ... and medical device sales leadership. He has received industry recognition for innovations and ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... many of the health care industry’s hospitals and provider groups, has announced that ... for select customers. Parasail Health is a San Francisco health-finance startup that has ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/30/2017)... Holdings, Inc. (NYSE: HRC), will present at the Goldman Sachs ... 13, 2017, in Rancho Palos Verdes, California ... officer, is scheduled to present at 3:20 p.m. Pacific Time. ... http://ir.hill-rom.com/events.cfm . A recorded replay will be available one ... 2017. About Hill-Rom ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
Breaking Medicine Technology: